Citi analyst Geoff Meacham raised the firm’s price target on Amgen (AMGN) to $345 from $315 and keeps a Neutral rating on the shares. The firm cites the company’s “strong” Q4 results for the target boost.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating
- Closing Bell Movers: AMD down 8% on earnings despite beat
- Amgen reports Q4 adjusted EPS $5.29, consensus $4.76
- Amgen sees FY26 adjusted EPS $21.60-$23.00, consensus $22.14
- Amgen sees FY26 CapEx $2.6B; share repurchases not to exceed $3B